Agencies Unite to Fight COVID-19 by Rapidly Sharing SARS-CoV-2 Virus Samples and Materials


2021 Interagency Partnership Award – HHS Agencies



Shortly after SARS-CoV-2 was identified as the viral agent that causes coronavirus disease 2019 (COVID-19), HHS agencies received intense demand for viral samples, diagnostic assays, and related material. To meet the critical need to share and distribute viral samples and other materials, the National Institute of Allergy and Infectious Diseases' (NIAID's) Technology Transfer Office (TTIPO), the Centers for Disease Control and Prevention (CDC), and HHS Office of Global Affairs mobilized to receive


and share coronavirus samples.

22 Organizations, including NIAID and CDC, provide SARS-CoV-2 materials to a Central Repository



Emergency Use Simple Letter Agreement (EUSLA)

 Broad use terms - minimize negotiation time



Central Repository

- Receive, culture, and validate
- Fulfilled 8,441 requests for materials

4,108 EUSLAs negotiated with 319 universities, 509 companies, 39 federal and state agencies, 5 foreign governments, and hospitals/non-profits

Materials distributed to 43 countries, 49 US states, and Puerto Rico



Samples received by the Repository supported validation of serology tests prior to FDA Approval

Supported many diagnostic Emergency Use Authorization packages for evaluation by the FDA Transfers of SARS-CoV-2 strains and other reagents supported basic research and many efficacy studies for vaccine and therapeutic development